Breast Cancer | Specialty

The OncLive Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

Treatment Patterns of Metastatic Triple-Negative Breast Cancer in US Community Practice Settings

April 18th 2012

First-line treatment patterns for metastatic triple-negative breast cancer are diverse, reflecting a lack of consensus and an unmet need for standardized therapy.

Dr. Whitworth on Treating Breast Cancer With Chemo

April 17th 2012

Dr. Pat Whitworth, from the Vanderbilt University Medical Center, Discusses Chemotherapy for Breast Cancer

When Patients Refuse Treatment for Their Cancer

April 15th 2012

Quoting statistics seemed to be a refuge to me. The objectivity of the numbers provided a hiding place and a shelter, and they helped me maintain the emotional distance that my profession demanded.

Dr. Mamounas on Predicting the Risk of DCIS Recurrence

April 12th 2012

Dr. Eleftherios Mamounas, from Aultman Hospital Cancer Center, on Predicting the Risk of DCIS Recurrence

Dr. Spector Discusses the Systemic Nature of Cancer

April 10th 2012

Dr. Neil Spector, from Duke Cancer Institute, Discusses the Systemic Nature of Cancer

Personalized Medicine: A Promising Future in Oncology Practice

April 10th 2012

This issue of Contemporary Oncology includes a focus on 2 challenging situations: management of metastatic TNBC and of advanced stage NSCLC.

Dual Inhibitors Explored in Triple-Negative Tumors

April 9th 2012

The use of advanced gene analysis techniques in a small group of women with triple-negative metastatic breast cancer has revealed activity in two pathways found in most patients with this subtype.

New Test Provides More Complete Picture of Recurrence Risk for DCIS

April 4th 2012

A new test specifically designed for breast cancer patients with DCIS appears to be a better indicator of recurrence than other assays for more invasive forms of the disease.

Chemotherapy-Related Fatigue Persists Over Time

April 4th 2012

Patients who undergo chemotherapy for breast cancer may develop fatigue that remains problematic long after they complete treatment.

Adjuvant Chemotherapy in Breast Cancer-Or Not?

April 3rd 2012

Adjuvant chemotherapy improves disease-free and overall survival in many--but not all--patients with breast cancer.

Dr. Dixon Discusses Making Mastectomy Decisions

April 2nd 2012

Dr. J. Michael Dixon, from the University of Edinburgh, Discusses Making the Decision to have a Mastectomy

Targeted Therapies in Breast Cancer Offer Increasing Hope and Complexity

April 2nd 2012

As research progresses, optimal treatment of breast cancer will involve individualization of therapy to focus on specific targets driving each patient's cancer.

Dr. Perou on Next Generation Sequencing Technology

March 30th 2012

Dr. Charles Perou, from the UNC Lineberger Comprehensive Cancer Center, on Next Generation Sequencing Technology

Dr. Gralow on Treating Breast Cancer Bone Metastases

March 29th 2012

Dr. Julie Gralow, from the Seattle Cancer Care Alliance, on Treating Breast Cancer Bone Metastases

Molecular Profiling Helps Determine Use of New Therapeutic Agents in Breast Cancer

March 29th 2012

For locally advanced breast cancer, molecular profiling may be an effective way to determine which patients respond better to certain therapies.

Dr. Perez on Patient Selection for Adjuvant Chemotherapy

March 28th 2012

Dr. Edith Perez, from the Mayo Clinic Cancer Center, Discusses Adjuvant Chemotherapy Patient Selection

Dr. Ellis Describes Breast Cancer Heterogeneity

March 27th 2012

Dr. Matthew Ellis, from Siteman Cancer Center, Describes Breast Cancer Heterogeneity

Supreme Court Asks for Reconsideration on BRCA1 and BRCA2 Patents

March 27th 2012

The US Supreme Court has asked an appellate court to reconsider its decision regarding patents held on two genes.

Examining the HER2 Testing Puzzle: Fresh Research Explores Nagging Questions

March 27th 2012

HER2 status in patients with breast cancer has emerged as a durable and effective marker for evaluating tumors and selecting therapies.

Dr. Spector Discusses the Complexities of Cancer

March 26th 2012

Dr. Neil Spector, from the Duke Cancer Institute, Discusses the Complexities of Cancer